Hepatocellular carcinoma (HCC) is a common malignancy and one of the leading causes of
cancer-related death. The biological process of HCC is complex, with multiple factors …

The last 3 years have seen the emergence of promising targeted therapies for the treatment
of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a …

Background: Liver cancer is one of the leading causes of cancer-related deaths worldwide.
The primary causes of liver cancer include hepatitis B virus (HBV), hepatitis C virus (HCV) …

The poor outcome of patients with non-surgically removable advanced hepatocellular
carcinoma (HCC), the most frequent type of primary liver cancer, is mainly due to the high …

Sorafenib has been considered the standard of care for patients with advanced
unresectable hepatocellular carcinoma (HCC) since 2007 and numerous studies have …

Despite advances in biomedicine, the incidence and the mortality of hepatocellular
carcinoma (HCC) remain high. The majority of HCC cases are diagnosed in later stages …

Sorafenib, an orally-available kinase inhibitor, is the only standard clinical treatment against
advanced hepatocellular carcinoma. However, development of resistance to sorafenib has …

Hepatocellular carcinoma (HCC) is the typical inflammation-induced neoplasia. It often
prospers where a chronic liver disease persists, thus leading a strong rationale for immune …

The tyrosine kinase inhibitor (TKI) sorafenib continues to be the anchor drug in the treatment
of advanced stage hepatocellular carcinoma (HCC). Other TKIs as well as immune …

Lenvatinib is a multitargeted tyrosine kinase inhibitor capable of promoting apoptosis,
suppressing angiogenesis, inhibiting tumor cell proliferation, and modulating the immune …